Details of Disease

General Information of Disease (ID: DISEOA7S)

• Disease Name: Lipid metabolism disorder
• Synonyms: fatty acid metabolism disorder; lipid metabolism disorder; dyslipidemia; dyslipidaemia; disorder of lipid metabolism
• Disease Class: 5C52: Inborn lipid metabolism error
• Definition: An inherited metabolic disorder caused by an enzyme deficiency, resulting in an inability to oxidize fatty acids for energy production.
• Disease Hierarchy:
  DISO5FAY: Inborn error of metabolism
  DISEOA7S: Lipid metabolism disorder
• ICD Code:
  ICD-11: ICD-11: 5C52.Z
  Expand ICD-10: E78,I00,I01,I02,I03,I04,I05,I06,I07,I08,I09,I10,I11,I12,I13,I14,I15,I16,I17,I18,I19,I20,I21,I22,I23,I24,I25,I26,I27,I28,I29,I30,I31,I32,I33,I34,I35,I36,I37,I38,I39,I40,I41,I42,I43,I44,I45,I46,I47,I48,I49,I50,I51,I52,I53,I54,I55,I56,I57,I58,I59,I60,I61,I62,I63,I64,I65,I66,I67,I68,I69,I70,I71,I72,I73,I74,I75,I76,I77,I78,I79,I80,I81,I82,I83,I84,I85,I86,I87,I88,I89,I90,I91,I92,I93,I94,I95,I96,I97,I98,I99
  Expand ICD-9: 272,390,391,392,393,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000
• Disease Identifiers:
  MONDO ID: MONDO_0002525
  MESH ID: D052439
  UMLS CUI: C0154251
  MedGen ID: 57587
  Orphanet ID: 309005
  SNOMED CT ID: 267431006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lipobean	DMA178I	Approved	NA	[1]
Pemafibrate	DMD1VZL	Approved	NA	[2]
Vitamin B3	DMQVRZH	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 9 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A-3309	DM4OHMP	Phase 3	NA	[4]
ZYH-1	DMMBJYC	Phase 3	NA	[5]
Aramchol	DMDLGRO	Phase 2/3	Small molecular drug	[6]
CP-778875	DM2O9VV	Phase 2	NA	[7]
GW-42004	DMY3KSU	Phase 2	NA	[8]
JTT-302	DMGLVBI	Phase 2	NA	[9]
ZYH7	DMG7YI9	Phase 2	Small molecular drug	[10]
BMS-816336	DM2WMJ7	Phase 1	NA	[11]
ZYT-1	DM1XOZK	Phase 1	NA	[12]

This Disease is Treated as An Indication in 9 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AZD-4121	DM3FKLV	Discontinued in Phase 1	NA	[13]
AZD-4619	DMZO3PU	Discontinued in Phase 1	Small molecular drug	[14]
LY-929	DMVYG5X	Discontinued in Phase 1	Small molecular drug	[15]
MP-136	DMK91WR	Discontinued in Phase 1	NA	[16]
RG-7273	DMXMQAT	Discontinued in Phase 1	NA	[17]
AZD-8294	DMUCOCH	Terminated	NA	[20]
KB-5359	DMM7S3V	Terminated	NA	[21]
KRP-105	DMVZSAM	Terminated	NA	[22]
LAG-078	DMYUU76	Terminated	NA	[23]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AZD-8450	DMG4XFB	Preclinical	NA	[18]
MC-3001	DMLK2D0	Preclinical	NA	[19]

This Disease is Treated as An Indication in 8 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A-922500	DM97YPL	Investigative	Small molecular drug	[24]
AP-02-00	DMCDXD1	Investigative	NA	[24]
CAT-2000	DMVTU3E	Investigative	NA	[24]
DRL-21994	DMHEQFW	Investigative	NA	[24]
DRL-21995	DMGM57J	Investigative	NA	[24]
GRC-9332	DMTI0JE	Investigative	NA	[24]
LAP-001	DMTXF4C	Investigative	NA	[24]
PRB-6014	DMTQAJF	Investigative	NA	[24]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 17 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
APOA1	TT5S8DR	Limited	Genetic Variation	[25]
HMGCR	TTPADOQ	Limited	Biomarker	[26]
APOB	TTN1IE2	moderate	Genetic Variation	[27]
CYP51A1	TT67TDP	moderate	Altered Expression	[28]
DGAT2	TTRHEQ4	moderate	Altered Expression	[29]
LCAT	TTGZ91P	moderate	Genetic Variation	[30]
LIPA	TTS8T1M	moderate	Biomarker	[31]
PPARA	TTJ584C	moderate	Altered Expression	[32]
RXRG	TTH029C	moderate	Genetic Variation	[33]
APOA2	TTGQA9W	Strong	Genetic Variation	[34]
APOC3	TTXOZQ1	Strong	Genetic Variation	[35]
AZGP1	TTUPYLV	Strong	Biomarker	[36]
HSP90AB1	TTH5YN2	Strong	Biomarker	[37]
LDLR	TTH0DUS	Strong	Genetic Variation	[38]
LPA	TTU9LGY	Strong	Genetic Variation	[39]
LPL	TTOF3WZ	Strong	Altered Expression	[40]
SREBF1	TTER0UB	Strong	Biomarker	[41]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYB5R3	DE4A3BL	moderate	Biomarker	[42]

This Disease Is Related to 10 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CPT2	OTIN6G20	Limited	Biomarker	[43]
ACOX1	OTM0A0DY	moderate	Altered Expression	[32]
APOA5	OTEVKLVA	moderate	Genetic Variation	[44]
IARS1	OT9WXH5N	moderate	Altered Expression	[45]
OPN1MW	OTPJ7LX4	moderate	Altered Expression	[46]
HADHB	OT4Y1I62	Strong	Biomarker	[47]
LDLRAP1	OT6QTX7R	Strong	Genetic Variation	[48]
PAQR3	OTTKJ9Y4	Strong	Posttranslational Modification	[49]
SOCS7	OT503VJG	Strong	Genetic Variation	[50]
PRM3	OT6574BF	Definitive	Biomarker	[51]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032781)
• [3] Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
• [4] ClinicalTrials.gov (NCT01895543) Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation. U.S. National Institutes of Health.
• [5] A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 g compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014 Feb;16(2):63-71.
• [6] ClinicalTrials.gov (NCT02279524) A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT00326326) Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.. U.S. National Institutes of Health.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036909)
• [9] ClinicalTrials.gov (NCT00748852) Safety Study of JTT-302 in Subjects With Low HDL-C Levels. U.S. National Institutes of Health.
• [10] ClinicalTrials.gov (NCT01539616) A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT00979368) Safety Study of BMS-816336 in Healthy Male Subjects. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT01543269) A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers. U.S. National Institutes of Health.
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026709)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7821).
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2657).
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031057)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031594)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019716)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021175)
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019721)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020270)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026674)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016555)
• [24] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [25] Genetic association of the ApoB and ApoA1 gene polymorphisms with the risk for alcohol-induced osteonecrosis of femoral head.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11332-9. eCollection 2015.
• [26] Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal.J Cell Physiol. 2019 Feb;234(2):1219-1229. doi: 10.1002/jcp.27121. Epub 2018 Sep 10.
• [27] Does lifestyle contribute to disease severity in patients with inherited lipid disorders?.Curr Opin Lipidol. 2017 Apr;28(2):177-185. doi: 10.1097/MOL.0000000000000387.
• [28] Effects of penthiopyrad on the development and behaviour of zebrafish in early-life stages.Chemosphere. 2019 Jan;214:184-194. doi: 10.1016/j.chemosphere.2018.09.117. Epub 2018 Sep 19.
• [29] Tangduqing Granules Attenuate Insulin Resistance and Abnormal Lipid Metabolism through the Coordinated Regulation of PPAR and DGAT2 in Type 2 Diabetic Rats.J Diabetes Res. 2019 Mar 25;2019:7403978. doi: 10.1155/2019/7403978. eCollection 2019.
• [30] In vitro expression of natural mutants of human lecithin:cholesterol acyltransferase.J Lipid Res. 1995 May;36(5):967-74.
• [31] Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency.Am J Cardiovasc Drugs. 2017 Jun;17(3):217-231. doi: 10.1007/s40256-017-0216-5.
• [32] Influence of total polar compounds on lipid metabolism, oxidative stress and cytotoxicity in HepG2 cells.Lipids Health Dis. 2019 Feb 1;18(1):37. doi: 10.1186/s12944-019-0980-0.
• [33] Mutation screening and association of human retinoid X receptor gamma variation with lipid levels in familial type 2 diabetes.Mol Genet Metab. 2002 May;76(1):14-22. doi: 10.1016/s1096-7192(02)00016-1.
• [34] APOA II genotypes frequency and their interaction with saturated fatty acids consumption on lipid profile of patients with type 2 diabetes.Clin Nutr. 2016 Aug;35(4):907-11. doi: 10.1016/j.clnu.2015.06.008. Epub 2015 Jul 16.
• [35] Genetic variants of APOC3 promoter and HLA-B genes in an HIV infected cohort in northern South Africa: a pilot study.Int J Mol Sci. 2014 Jun 26;15(7):11403-15. doi: 10.3390/ijms150711403.
• [36] Serum zinc-2-glycoprotein levels are elevated and correlated with thyroid hormone in newly diagnosed hyperthyroidism.BMC Endocr Disord. 2019 Jan 22;19(1):12. doi: 10.1186/s12902-019-0336-9.
• [37] Inhibition of HSP90 Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System.Theranostics. 2019 Aug 12;9(20):5769-5783. doi: 10.7150/thno.36505. eCollection 2019.
• [38] The development and first results of a health-related outcomes set in familial hypercholesterolemia (FH) patients: Knowledge is health.Atherosclerosis. 2020 Jan;293:11-17. doi: 10.1016/j.atherosclerosis.2019.11.030. Epub 2019 Nov 30.
• [39] Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.Clin Cardiol. 2018 Mar;41(3):378-384. doi: 10.1002/clc.22880. Epub 2018 Feb 26.
• [40] Effects of Portulaca Oleracea Extract on Acute Alcoholic Liver Injury of Rats.Molecules. 2019 Aug 8;24(16):2887. doi: 10.3390/molecules24162887.
• [41] SREBP-1 and LXR pathways mediated Cu-induced hepatic lipid metabolism in zebrafish Danio rerio.Chemosphere. 2019 Jan;215:370-379. doi: 10.1016/j.chemosphere.2018.10.058. Epub 2018 Oct 10.
• [42] Cellular and Molecular Mechanisms of Recessive Hereditary Methaemoglobinaemia Type II.J Clin Med. 2018 Oct 10;7(10):341. doi: 10.3390/jcm7100341.
• [43] Coexistence of VHL Disease and CPT2 Deficiency: A Case Report.Cancer Res Treat. 2016 Oct;48(4):1438-1442. doi: 10.4143/crt.2015.450. Epub 2016 Mar 25.
• [44] Association of apolipoprotein A5 genetic polymorphisms with steroid-induced osteonecrosis of femoral head in a Chinese Han population.Diagn Pathol. 2014 Dec 17;9:229. doi: 10.1186/s13000-014-0229-1.
• [45] Taurine Improves Lipid Metabolism and Skeletal Muscle Sensitivity to Insulin in Rats Fed with High Sugar and High Fat Diet.Adv Exp Med Biol. 2019;1155:133-146. doi: 10.1007/978-981-13-8023-5_12.
• [46] 4-O-Sulfation in sea cucumber fucodians contribute to reversing dyslipidiaemia caused by HFD.Int J Biol Macromol. 2017 Jun;99:96-104. doi: 10.1016/j.ijbiomac.2017.01.145. Epub 2017 Feb 1.
• [47] ENU mutagenesis identifies mice with cardiac fibrosis and hepatic steatosis caused by a mutation in the mitochondrial trifunctional protein beta-subunit.Hum Mol Genet. 2006 Dec 15;15(24):3569-77. doi: 10.1093/hmg/ddl433. Epub 2006 Nov 20.
• [48] Genetic epidemiology of autosomal recessive hypercholesterolemia in Sicily: Identification by next-generation sequencing of a new kindred.J Clin Lipidol. 2018 Jan-Feb;12(1):145-151. doi: 10.1016/j.jacl.2017.10.014. Epub 2017 Oct 27.
• [49] PAQR3 regulates phosphorylation of FoxO1 in insulin-resistant HepG2 cells via NF-B signaling pathway.Exp Cell Res. 2019 Aug 15;381(2):301-310. doi: 10.1016/j.yexcr.2019.04.031. Epub 2019 May 13.
• [50] Common variants in SOCS7 gene predict obesity, disturbances in lipid metabolism and insulin resistance.Nutr Metab Cardiovasc Dis. 2013 May;23(5):424-31. doi: 10.1016/j.numecd.2011.10.005. Epub 2012 Mar 6.
• [51] Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases.Biochem Pharmacol. 2008 Jun 15;75(12):2263-75. doi: 10.1016/j.bcp.2008.03.004. Epub 2008 Mar 15.